Benchmark sees long-term growth in aquaculture

0
29
  • Benchmark Holdings enjoying good momentum across the business
  • Benchmark Holdings quarter results show ‘continued progress we’ve shown throughout the year’
salmon

Quick facts: Benchmark Holdings PLC

Follow

View company profile

Benchmark’s mission is to enable aquaculture producers to improve their sustainability and profitability. We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock – from broodstock and hatchery through to nursery and grow out. Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments.

24 Aug 2021

() saw revenue rise 17% year-on-year in the April-June quarter, with the group seeing strong performance across all business areas.

The aquaculture biotechnology business said revenue from continuing operations in what is the third quarter of the group’s fiscal year rose 25% on a constant exchange rates (CER) basis to GBP28.3mln from a restated GBP24.1mln in the same quarter of 2020.

Adjusted underlying earnings (EBITDA) jumped 110% (+ 123% CER) to GBP4.4mln from a restated GBP2.1mln the previous year. Excluding changes in the book value of biological assets, adjusted EBITDA was up 37% (CER: +47%) at GBP4.1mln from GBP3.0mln a year earlier.

The statutory loss before tax from continuing operations narrowed to GBP2.7mln from GBP6.2mln in the third quarter of the previous fiscal year.

Read more

02 Jul 2021

() said it had received marketing authorisation from the Norwegian Medicines Agency (NoMA) for EctosanVet (BMK08), its pioneering treatment for sea lice in salmon.

Sea lice are one of the biggest biological challenges in salmon farming, said Benchmark, and estimated to cost producers more than US$1bn annually, and US$600mln in Norway alone.

Read more

18 May 2021

(), the aquaculture biotechnology company, saw growth in revenues and earnings in the six months to the end of March.

Revenue from continuing operations rose to GBP59.5mln from GBP56.2mln in the corresponding period a year earlier. Had exchange rates stayed the same from a year earlier, revenue would have been up 11% year-on-year at GBP62.3mln.

Read more

24 Aug 2021

()’s () CEO Trond Williksen and CFO Septima Maguire talk to Proactive London’s Katie Pilbeam about their April-June quarter, with the group seeing strong performance across all business areas.

The firm saw revenue rise 17% year-on-year from continuing operations in what is the third quarter of the group’s fiscal year rose 25% on a constant exchange rates (CER) basis to GBP28.3mln from a restated GBP24.1mln in the same quarter of 2020.

Adjusted underlying earnings (EBITDA) jumped 110% (+ 123% CER) to GBP4.4mln from a restated GBP2.1mln the previous year. Excluding changes in the book value of biological assets, adjusted EBITDA was up 37% (CER: +47%) at GBP4.1mln from GBP3.0mln a year earlier.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Benchmark Holdings quarter results show ‘continued progress we’ve shown…

Benchmark Holdings PLC (AIM:BMK)’s (LON:BMK) CEO Trond Williksen and CFO Septima Maguire talk to Proactive London’s Katie Pilbeam about their April-June quarter, with the group seeing strong performance across all business areas.

The firm saw revenue rise 17% year-on-year from continuing…

20 hours, 55 minutes ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here